Aim Schizophrenia is a mental disorder and one of the suspected causes is cytokines. One of them is tumour necrosis factor-alpha (TNF-α). Cytokines have the potential to affect cognitive function. The study aimed to find a correlation of TNF-α level with the Mini-Mental State Examination (MMSE) score in patients with schizophrenia (PwS), and comparing the level of TNF-α levels between PwS and healthy controls. Methods We conducted a cross-sectional analytic study and the study designs were correlation and comparative analysis, i.e. using a Mann-Whitney U test. A total number of 100 subjects were collected, and they were divided into two groups of PwS and control group, respectively. Results The results found that most of the PwS subjects were 39 men (78.0%), while the control group were 28 men (56.%). The differences in TNF-α levels between PwS and control groups were found to be significant p <0.001, there was no significant correlation between TNF-α level and the score of MMSE of the PwS with p = 0.938, with a very weak correlation that was r = -0.011, and a negative correlation direction. Conclusion There was a significant difference between TNF-α level of PwS and control group, i.e. PwS group had lower TNF-α level compared to the control group. The TNF-α level of PwS group had a very weak effect on the cause of cognitive dysfunction in PwS group, yet the higher level of it could reduce MMSE score in PwS group.
Gupta S, Kulhara P. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Vol. 52, Indian J Psychiatry. 2010. p. 21–7.
3.
Nawa H, Takahashi M, Paterson PH. Cytokine and growth factor involvement in schizophrenia – support for the developmental model. Vol. 5, Mol Psychiatry. 2000. p. 594–603.
4.
Naudin J, Capo C, Giusan B, Mège JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Vol. 26, Schizophr Res. 1997. p. 227–33.
5.
Erbagci AB, Herken H, Köyloüglu O, Yilmaz N, IL-1β TMS, sIL-2R. IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Vol. 10, Mediators Inflamm. 2001. p. 109–15.
6.
Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Vol. 50, Schizophr Res. 2001. p. 169–75.
7.
Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Vol. 47, Schizophr Res. 2001. p. 13–25.
8.
O’Brien SM, Dinan SP, T.G. Increased tumor necrosis factor-alpha concentrations in excacerbations of schizophrenia. Vol. 160, Psychiatry Res. 2008. p. 256–62.
9.
Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, Dmitrzak-Węglarz M, Leszczyńska-Rodziewicz A, et al. Association of tumor necrosis factor – 308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Vol. 57, Neuropsychobiology. 2008. p. 88–94.
10.
M.d.R GM, J PM, B LC, F SR, P PM, A OC, et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. Vol. 4, J Psychiatric Res. 2010. p. 441–6.
11.
Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Vol. 7, Expert Rev Neurother. 2007. p. 789–96.
12.
Baune BT, Camara ML, Jawahar C, Anscomb H, Körner H. Tumour necrosis factor-alpha mediated mechanisms of cognitive dysfunctions. Vol. 3, Transl Neurosci. 2012. p. 263–77.
13.
Xiu MH, Man LJ, Wang D, Du X, Yin G, Zhang Y, et al. Tumor necrosis factor-alpha-1031T/C polymorphism is associated with cognitive deficits in chronic schizophrenia patients with healthy controls. Vol. 2018, Am J Med Genet B Neuropsychiatr Genet.
14.
Organization WH. The ICD-10 classification of mental and behavioural disorders. 1992.
15.
Folstein M, Folsten S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patient for the clinician. Vol. 12, J Psychiatry Res. 1975. p. 189–98.
16.
Indonesia KP. Modul psikiatri geriatri (Geriatric psychiatry module. 2008.
17.
Lv MH, Y.L T, Yan SX, Tian L, Chen DC, Tan SP, et al. Decreased serum TNFalpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition. Vol. 232, Psychopharmacol. 2015. p. 165–72.
18.
Kunz M, Ceresér KM, Goi PD, Fries GR, Teixera AL, Fernandes BS, et al. Serum levels of IL-6, IL-10, TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Vol. 33, Braz J Psychiatry. 2011. p. 268–74.
19.
Tian L, Tan Y, Chen D, Lv M, Tan S, Soares JC, et al. Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. Vol. 54. 2014.
20.
Kubistova A, Horacek J, Novak T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Vol. 24, Psychiatr Danub. 2012. p. 153–6.
21.
Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Vol. 11, Bipolar Disord. 2009. p. 726–34.
22.
Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Vol. 2012, Schizophr Res Treatment. 2012.
23.
Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? Vol. 1, J Transl Neurosci. 2016. p. 37–42.
24.
Chiang SSW, Riedel M, Gruber R, Müller N, Schwarz M. In vivo type II T-helper cells shift in schizophrenia compared to sex- and age-matched healthy controls. Vol. 25, Eur J Psychiatry. 2011. p. 192–204.
25.
Zhu F, Zhang L, Liu F, Wu R, Guo W, Ou J, et al. Altered serum tumor necrosis factor and interleukin-1β in first-episode drug-naïve and chronic schizophrenia. Vol. 12, Front Neurosci. 2018.
26.
Boerrigter D, Weickert TW, Lenroot R, O’Donnell M, Galletly C, Liu D, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. Vol. 14, J Neuroinflamm. 2017. p. 1–15.
27.
Lee EE, Hong S, Martin AS, Eyler LT, Jeste DV. Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. Vol. 25, Am J Geriatr Psychiatry. 2017. p. 50–61.
28.
Ergün S, Yanartas Ö, Kandemir G, Yaman A, Yildiz M, Haklar G, et al. The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia. Vol. 28, Psychiatry Clin Psychopharmacol. 2018. p. 66–72.
29.
Simamora RH, Loebis B, Husada MS. Comparison of serum levels of tumor necrosis factor alpha (TNF-α) in Batak male schizophrenic patients versus healthy controls. Vol. 4, Int J Life Sci Scienti Res. 2018. p. 1652–6.
30.
Trovão N, Prata J, VonDoellinger O, Santos S, Barbosa M, Coelho R. Peripheral biomarkers for firstepisode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia. Vol. 16, Psychiatry Investig. 2018. p. 177–84.
31.
Xu H. Neuroinflammation in schizophrenia focused on the pharmacological and therapeutic evidence. Vol. 6, Pharmacol. 2015. p. 438–53.
32.
R TH, M J, SP S, M O, MA S, Y L, et al. Host and environmental factors influencing individual human cytokine responses. Vol. 167, Cell. 2016. p. 1111–24.
33.
Mansur RB, Zugman A, Asevedo EM, Cunha GR, Bressan RA, Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Vol. 66, Psychiatry Clin Neurosci. 2012. p. 247–60.
34.
Pollmächer T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines-do they affect human brain functions? Vol. 16, Brain Behav Immun. 2002. p. 525–32.
35.
Hoseth EZ, Ueland T, Dieset I, Birnbaum R, Shin JH, Kleinman JE, et al. A study of TNF pathway activation in schizophrenia and bipolar disorder in plasma and brain tissue. Vol. 43, Schizophr Bull. 2017. p. 881–90.
36.
Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease state and inflammation.
37.
Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Vol. 39, Schizophr Bull. 2013. p. 1174–9.
38.
Hennessy E, Gormley S, Lopez-Rodriguez AB, Murray C, Murray C, Cunningham C. Systemic TNF-α produce acute cognitive dysfunction and exaggerated sickness behaviour when superimposed upon progressive neurodegeneration. Vol. 59, Brain Behav Immun. 2017. p. 233–44.
39.
Şahin TD, Karson A, Balci F, Yazir Y, Bayramgürler D, Utkan T. TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression. Vol. 292, Behav Brain Res. 2015. p. 233–40.
40.
Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH, et al. TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. Vol. 9, J Neuroinflamm. 2012.
41.
Thomasy H. Tumor necrosis factor α as a potential mediator of the effects of phosphodiesterase 4B inhibition on cognition after traumatic brain injury. Vol. 36, J Neurosci. 2016. p. 11587–9.
42.
Miller BJ, Culpepper N, Rapaport MH, Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Vol. 42, Prog Neuropsychopharmacol Biol Psychiatry. 2013. p. 92–100.
43.
Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Vol. 192, Schizophr Res. 2018. p. 16–29.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
